Benjamin P. Levy, MD:This patient is a 53-year-old never-smoking female who presented to her primary care physician with left shoulder pain, as well as fatigue and cough. The primary care physician treated the patient with a course of antibiotics with a presumed pneumonia diagnosis that did not improve. This led to a chest X-ray that revealed a left upper lobe opacity. This was followed by a CAT scan, which, unfortunately, revealed a 5-cm left upper lobe mass, as well as some mediastinal adenopathy. Because of the findings on the CAT scan, the patient had a core needle biopsy of the left upper lobe that, surprisingly, revealedP63-positive squamous cell lung cancerTTF-1negative.
The tissue was sent off for molecular testing and was negative. The PD-L1 was also sent out and was 0%. The patient subsequently went on to receive a staging workup with both a PET/CT and a brain MRI. The brain MRI was negative for any intraparenchymal metastases.
Unfortunately, the PET/CT did show a liver lesion and an adrenal lesion. Because the patient had no actionable mutation, the PD-L1 expression was less than 50%, and because the PET/CT scan revealed advanced stage disease, the patient was started on cytotoxic chemotherapy with cisplatin and gemcitabine.
Transcript edited for clarity.
Case: A 53-Year-Old Woman with mNSCLC Rapid Progression
TTFields Increases Time to Progression in Patients With Brain Metastases From NSCLC
March 27th 2024Findings from the phase 3 METIS trial found that tumor-treating fields were able to significantly improve time to intracranial progression in patients with brain metastases from non-small cell lung cancer.
Read More
Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC
March 25th 2024During a Case-Based Roundtable® event, Christine, Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non–small cell lung cancer in the first article of a 2-part series.
Read More
Newer TKIs Show Better Intracranial Responses in ROS1+ NSCLC
March 13th 2024In the first article of a 2-part series, Christine Bestvina, MD, discussed the role of the newer tyrosine kinase inhibitor repotrectinib for patients with non–small cell lung cancer that is positive for a ROS1 mutation.
Read More